Zomedica Corp. (AMEX: ZOM) has revealed today the date of the marketing of TRUFORMA™. The drug manufacturer disclosed that it is planning to commence the launch of the TRUFORMA™ point-of-care diagnostic platform on March 30, 2021.

From the last few months, the company has strived to bring the diagnostic platform to the market, and finally, it got a chance to market its diagnostic platform. The TRUFORMA platform of the company is being developed by using the Bulk Acoustic wave (BAW) technology which is developed by Qorvo. This technology is not only embedded in mobile phones but also in advanced radar and communications systems around the globe.

The diagnostic platform of the company is secured by 70 issued and pending patents. Zomedica Corp believed that this platform of the company would be very useful for the detection and diagnosis of diseases. TRUFORMA is the first platform that uses BAW technology to help in diagnosis.

Shares of Zomedica Corp. (AMEX: ZOM) soared 57.87% at $0.1257 during the pre-market trading session of Friday. It has recorded a trading volume of 19.46 million as compared to the average volume of 23.41 million. In the past 52-weeks of trading, this company’s stock has fluctuated between the low of $0.06 and a high of $0.50. Zomedica market capitalization has remained high, hitting $47.76 million at the time of writing.

The company is currently involved in the development of five assays including two panels one each to identify thyroid and adrenal disease. Zomedica has also finalized authentication for canine and feline TSH, canine and feline tT4, canine fT4 and canine cortisol assays, and certification efforts are being made for all of these tests.

The drug manufacturer is currently working on the building of its sales organization for the market launch of its product. Earlier, it has been disclosed that this organization will consist of direct sales representatives, professional service veterinarians, distributors, distributor support representatives. Zomedica will fully provide support for the new organization.